PD-1/PD-L1信号通路在复发性或晚期子宫内膜癌中的研究进展  

Research Progress on the PD-1/PD-L1 Signaling Pathway in Recurrent or Advanced Endometrial Cancer

作　　者：吴群丹 郑燕茹 洪怨治 赵成飞 WU Qun-dan;ZHENG Yan-ru;HONG Yuan-zhi;ZHAO Cheng-fei(Quanzhou Skin Disease Prevention and Treatment Hospital,Quanzhou 362000,China;Yongchun County Hospital,Quanzhou 362000,China;Putian Uniwersity,Putian 351100,China)

机构地区：[1]泉州市皮肤病防治院,福建泉州362000 [2]永春县医院,福建泉州362000 [3]莆田学院,福建莆田351100

出　　处：《海峡药学》2024年第10期81-85,共5页Strait Pharmaceutical Journal

摘　　要：子宫内膜癌是女性生殖道中比较常见的恶性肿瘤之一,严重威胁着女性的健康。虽然早期发现和诊疗的子宫内膜癌通常表现出较高的治愈率,但复发性或晚期子宫内膜癌却面临着有限的治疗选择和较差的预后情况。因此,寻找新的治疗方法变得尤为重要。近年来,免疫疗法在复发性或晚期子宫内膜癌的临床试验中显示出了较好的疗效和安全性,因此本文将探讨PD-1/PD-L1信号通路在复发性或晚期子宫内膜癌中的最新研究进展,以期为临床治疗复发性或晚期子宫内膜癌提供新的治疗方案和思路。Endometrial cancer is one of the common malignant tumors in the female reproductive system,posing a serious threat to women′s health.Although endometrial cancer generally has a high cure rate,especially when detected and diagnosed early,recurrent or advanced endometrial cancer faces limited treatment options and poor prognosis.Therefore,the search for new treatment strategies becomes extremely important.In recent years,immune therapy has shown promising efficacy and safety in clinical trials for recurrent or advanced endometrial cancer.This article will discuss the latest research progress on the PD-1/PD-L1 signaling pathway in recurrent or advanced endometrial cancer,aiming to provide new treatment options and ideas for the clinical management of recurrent or advanced endometrial cancer.

关 键 词：复发性或晚期子宫内膜癌 PD-1/PD-L1信号通路 研究进展 

分 类 号：R969[医药卫生—药理学]